Millennium, Aventis Pharma form nove...( ion the outcome of litigation and the ...),Health

ion, the outcome of litigation and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in documents of Aventis on file with the Securities and Exchange Commission, as well as the Registration Statement on Form F-4 of Rhône-Poulenc, S.A. (the previous name of Aventis) and other documents of Rhône-Poulenc, S.A. and Hoechst AG on file with the Securities and Exchange Commission.

This press release contains "forward-looking statements." These statements include descriptions of Millennium's operational plans, expectations about future earnings and other results of operations, views of future industry or market conditions, and other statements that include words like "may," "expects," believes," and "intends," and that describe opinions about future events. Known and unknown risks may cause Millennium's actual results and performances to be materially different from those expressed or implied by these statements. Some of these risks are: uncertainties relating to unanticipated difficulties and delays relating to gene identification, drug discovery and clinical development processes; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes; uncertainties relating to patent protection and regulatory approval; and uncertainties relating to the ability of Millennium and its affiliates to obtain substantial additional funds required for progress in drug discovery and development. These and other factors are identified and more fully explained under the heading "Risk Factors That May Affect Results" in the annual report on Form 10-K filed by Millennium with the Securities and Exchange Commission on February 25, 2000.

'"/>

Contact: Sally McCraven, Millennium Pharmaceuticals, Inc.
617-577-3548
Porter Novelli
22-Jun-2000

Page: 1 2 3 4 5 6
Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Aventis Pasteur statement on HVTN 501 decision
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. 2005 Pharmacology, Therapeutics, & Toxicology Research Award
6. Pharmacist review does not keep older people out of hospital
7. Pharmaceutical marketing tactics hold little sway with prescribing physicians
8. Pharmacists want role in drug importation, study shows
9. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
10. 2004 Pharmacology/Therapeutics/Toxicology Award to Haas
11. Pharmacists play role in cholesterol control